Young Donor Plasma Transfusion and Age-Related Biomarkers

Ambrosia LLC

Status: Completed

Conditions: Aging

Treatments: Other: Plasma

Study type: Interventional

Funder types: Industry

Identifiers

NCT02803554

AM-PL-101

Details and patient eligibility

About

The purpose of the study is to evaluate the beneficial effects of infusions of plasma from young donors using blood biomarkers.

Full description

Each patient will receive an infusion of plasma derived from a young donor (16-25 years of age). A panel of age-associated biomarkers will be measured before and after treatment.

We have drawn biomarkers from clinical measures of aging and physiology, biomarkers of disease advancement, as well as biomarkers of aging from animal and human studies. These will represent a spectrum of physiologic pathways with evidence-based connections to aging. They include the physiologic processes of inflammation, neurogenesis, stem cell proliferation, blood clotting, immune function, and amyloid plaques. Organ function which will be specifically measured includes the liver, bone marrow, kidneys, pancreas, muscles, cardiovasculature, cerebrovasculature, and the thyroid. Specific disease states connected to these biomarkers include anemia, neutropenia, thrombocytopenia, obesity, diabetes, high cholesterol, elevated risk of cancer, atherosclerosis, dementia, and cataracts.

Visit us at www.ambrosiaplasma.com

Enrollment: 200 patients

Sex: All

Ages: 35+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• 35 years of age or older

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

200 participants in 1 patient group

Young donor plasma

Experimental group

Description:

An infusion of plasma derived from donors aged 25 years or younger

Treatment:

Other: Plasma